Keros Therapeutics, Inc.
KROS
$14.91
$0.151.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.17M | 211.25M | 3.04M | 388.00K | 37.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.17M | 211.25M | 3.04M | 388.00K | 37.00K |
| Cost of Revenue | 43.50M | 48.71M | -128.00M | 49.23M | 40.52M |
| Gross Profit | -25.34M | 162.54M | 131.04M | -48.84M | -40.48M |
| SG&A Expenses | 14.48M | 10.50M | 10.67M | 9.82M | 9.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.99M | 59.21M | 56.30M | 59.05M | 50.48M |
| Operating Income | -39.82M | 152.04M | -53.25M | -58.66M | -50.44M |
| Income Before Tax | -32.92M | 158.49M | -45.73M | -52.96M | -45.26M |
| Income Tax Expenses | -2.22M | 10.04M | 300.00K | -- | -- |
| Earnings from Continuing Operations | -30.70M | 148.45M | -46.03M | -52.96M | -45.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.70M | 148.45M | -46.03M | -52.96M | -45.26M |
| EBIT | -39.82M | 152.04M | -53.25M | -58.66M | -50.44M |
| EBITDA | -39.45M | 152.38M | -52.92M | -58.34M | -50.13M |
| EPS Basic | -0.76 | 3.66 | -1.14 | -1.41 | -1.25 |
| Normalized Basic EPS | -0.51 | 2.44 | -0.71 | -0.88 | -0.78 |
| EPS Diluted | -0.76 | 3.62 | -1.14 | -2.82 | -1.25 |
| Normalized Diluted EPS | -0.51 | 2.41 | -0.71 | -0.88 | -0.78 |
| Average Basic Shares Outstanding | 40.61M | 40.56M | 40.34M | 37.59M | 36.10M |
| Average Diluted Shares Outstanding | 40.61M | 41.02M | 40.34M | 37.59M | 36.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |